Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate the Diagnostic Efficacy and Safety of INR101 Injection for PET/CT Imaging in Detecting Preoperative Pelvic Lymph Node Metastasis in Patients With Prostate Cancer

NCT06922903 is registered in ClinicalTrials.gov with Yunhe Pharmaceutical (Tianjin) Co., Ltd as lead sponsor.

NCT NCT06922903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06922903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate the Diagnostic Efficacy and Safety of INR101 Injection for PET/CT Imaging in Detecting Preoperative Pelvic Lymph Node Metastasis in Patients With Prostate Cancer
Lead sponsor
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
April 30, 2025
Completion date
May 31, 2026
Enrollment
240 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer